meropenem and Inflammatory-Bowel-Diseases

Although meropenem is commonly used for intra-abdominal infections, its penetration into the abdominal cavity is not well understood. Meropenem (500 mg) was administered intravenously to 8 patients with inflammatory bowel diseases undergoing laparotomy. The drug concentrations were analyzed and used for a Monte Carlo simulation with minimum inhibitory concentration (MIC) data. Meropenem concentrations in peritoneal fluid (PF) and plasma were similar at 1 h after the end of a 0.5-h infusion. The probabilities of target achievement of drug concentrations over the MIC in PF for 40% of the dosing interval with 500 mg every 8 h and 1000 mg every 8 h, were 84% and 90% against Bacteroides spp., 98% and 99% against Escherichia coli , and 76% and 83% against Pseudomonas aeruginosa, respectively. In conclusion, meropenem penetrated PF well, and 500 mg every 8 h or 1000 mg every 8 h would be suitable for the therapy for intraabdominal infections.

Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Ascitic Fluid; Female; Gram-Negative Bacteria; Humans; Inflammatory Bowel Diseases; Male; Meropenem; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Thienamycins